An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

This study has been completed.
Isis Pharmaceuticals
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company ) Identifier:
First received: June 5, 2008
Last updated: February 3, 2015
Last verified: February 2015
To evaluate the safety and efficacy of extended dosing with mipomersen (ISIS 301012) in participants with familial hypercholesterolemia or severe hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS5 (NCT00607373), 301012-CS7 (NCT00706849), 301012-CS17 (NCT00477594) or MIPO3500108 (NCT00794664) clinical drug trials.

Condition Intervention Phase
Lipid Metabolism, Inborn Errors
Hypercholesterolemia, Autosomal Dominant
Metabolic Diseases
Hyperlipoproteinemia Type II
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Metabolic Disorder
Congenital Abnormalities
Lipid Metabolism Disorders
Drug: Mipomersen Sodium
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Percent reduction of low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B), total cholesterol and non-high-density lipoprotein cholesterol (non-HDL-C) at various timepoints [ Time Frame: Through up to four years of treatment and 24 weeks of follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Effects of mipomersen (ISIS 301012) on triglycerides, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein A-1 (apoA-1), lipoprotein (a) (Lp(a), lipoprotein sub-classes and high-sensitivity C-Reactive Protein [ Time Frame: Through up to four years of treatment and 24 weeks of follow-up ] [ Designated as safety issue: No ]

Enrollment: 142
Study Start Date: April 2008
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mipomersen Drug: Mipomersen Sodium
Mipomersen sodium 200 milligram (mg) (for participants weighed greater than or equal to [>=] 50 kilogram [kg]) or 160 mg (for participants weighed less than [<] 50 kg) once a week subcutaneously for up to 52 or 104 weeks (depending on participant's consent).
Other Name: ISIS 301012

Detailed Description:
All familial hypercholesterolemia (FH) or severe hypercholesterolemia participants who have tolerated the treatment regimen in Protocol 301012-CS5 (NCT00607373), 301012-CS7 (NCT00706849) or MIPO3500108 (NCT00794664) and satisfactorily completed the study through to Week 28 were eligible for participation in this open label treatment extension study for up to 4 years or until mipomersen is commercially available, whichever comes first. Consenting participants who have tolerated mipomersen and satisfactorily completed 301012-CS17 (NCT00477594) through Year 3 may also enroll for up to an additional 2 years of treatment in this study or until mipomersen is commercially available, whichever comes first. All participants, who entered the study, received 200 mg mipomersen (ISIS 301012) subcutaneously (s.c.) every week, including those who were randomized to placebo in their initial study. Participants who were originally enrolled in Protocol 301012-CS5 (NCT00607373) and weighed <50 kg received 160 mg every week. Dose adjustments (70 mg injections administered three times per week, on separate days) were allowed for participants who were not tolerating or who have had previous issues with tolerating the once a week injections due to injection site reactions (ISRs) or flu-like symptoms. Study visits and clinical lab assessments including hematology with differential, chemistry, serum lipid panel (total cholesterol, LDL-C, very low density lipoprotein cholesterol (VLDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein B (apoB), apoA-1, triglycerides (TG) and Lp(a), and urinalysis was to be performed every 4-10 weeks during the treatment period. Plasma trough mipomersen (ISIS 301012) levels was to be measured to estimate exposure. Participants who completed dosing or who discontinued prematurely from the study for any reason was followed for safety for 24 weeks (safety follow-up period) after their last dose of mipomersen (ISIS 301012) or longer in the case of a significant adverse events (AE) or abnormal biochemical or clinical finding. Participants was to be required to return to the study center for clinical evaluation and clinical laboratory tests every 8 weeks during the safety follow-up period.

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Satisfactory completion of dosing in their initial study (Protocol 301012-CS5 [NCT00607373], 301012-CS7 [NCT00706849], 301012-CS17 [NCT00477594], or MIPO3500108 [NCT00794664]).

Exclusion Criteria:

  • Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00694109

  Show 33 Study Locations
Sponsors and Collaborators
Genzyme, a Sanofi Company
Isis Pharmaceuticals
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

No publications provided by Sanofi

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sanofi ( Genzyme, a Sanofi Company ) Identifier: NCT00694109     History of Changes
Other Study ID Numbers: 301012-CS6, 2005-003450-10
Study First Received: June 5, 2008
Last Updated: February 3, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
South Africa: Medicines Control Council
Taiwan: Department of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Brazil: National Health Surveillance Agency
Singapore: Health Sciences Authority

Keywords provided by Sanofi:
Familial Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia

Additional relevant MeSH terms:
Congenital Abnormalities
Genetic Diseases, Inborn
Hyperlipoproteinemia Type II
Infant, Newborn, Diseases
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Metabolism, Inborn Errors
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Nervous System Diseases
Pathologic Processes
Anticholesteremic Agents
Diagnostic Uses of Chemicals
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on November 27, 2015